AVIRON Form 425 January 09, 2002

Pursuant to Rule 4

MedImmune Registration Statement for Aviron Acquisition Declared Ef

Gaithersburg, MD, January 9, 2002 -- MedImmune, Inc. (Nasdaq: MEDI) announced today that the Secunderland effective the registration statement MedImmune filed on December 10, 2001, as amended on acquisition of Aviron (Nasdaq: AVIR). As previously announced, MedImmune and Aviron have entered under which MedImmune will acquire Aviron through an exchange offer and merger transaction in whi 1.075 MedImmune shares for each Aviron share.

The exchange offer commenced on December 10, 2001 and is scheduled to expire at 12:00 midnight, N 9, 2002, unless extended. MedImmune expects to consummate the exchange offer at such time, subject conditions to the offer.

The Information Agent for the offer is MacKenzie Partners, Inc., 156 Fifth Avenue, New York, New 212-929-5500 or toll-free at 800-322-2885. The Dealer Manager for the offer is Merrill Lynch & Co New York, New York 10080. Call collect at 609-274-3066.

Aviron is a biopharmaceutical company headquartered in Mountain View, California, focused on previnnovative vaccine technologies. The company's product portfolio includes: FluMist, a live virus mist for the prevention of influenza; a live parainfluenza virus type 3 vaccine; a vaccine to pre cytomegalovirus vaccine. For more information on Aviron, visit the company's website at www.aviron

MedImmune, Inc. is a fully integrated biotechnology company focused on developing and marketing prints in areas such as infectious disease, immune regulation and cancer. Headquartered in Gaithersburg, manufacturing facilities in Frederick, Maryland and Nijmegen, the Netherlands. MedImmune markets Synagis® (palivizumab), which is marketed for the prevention of serious lower respiratory tract of syncytial virus in pediatric patients at high risk of RSV disease, which is prominent in the North through May (see full prescribing information at www.medimmune.com); Ethyol®, which is marketed for cumulative renal toxicity associated with repeated administration of cisplatin in patients with a cell lung cancer and moderate to severe xerostomia in patients undergoing post-operative radiation cancer, where the radiation port includes a substantial portion of the parotid (see full prescrib www.medimmune.com); and CytoGam®, which is marketed for the prophylaxis against cytomegalovirus of transplantation of kidney, lung, liver, pancreas, and heart (see full prescribing information at has six products in various stages of clinical testing for a number of diseases and several more testing. For more information on MedImmune, visit the company's website at www.medimmune.com.

This announcement may contain, in addition to historical information, certain forward-looking statements. Such statements reflect management's current views and are based on certain assumpt materially from those currently anticipated as a result of a number of factors, including risks at MedImmune's and Aviron's filings with the SEC. MedImmune and Aviron are developing products for pt can be no assurance that such development efforts will succeed, that such products will receive rethat, even if such regulatory clearance were received, such products would ultimately achieve compassurance that the offer and merger will close or that Aviron will be integrated successfully or

We urge Aviron stockholders and other investors to read the registration statement on Form S-4, S and other exchange offer documents which have been filed or will be filed by MedImmune with the S and the related solicitation/recommendation statement filed by Aviron with the SEC. These documen which should be read carefully before any decision is made with respect to the offer. Documents f free at the SEC's website at www.sec.gov. Documents are also available for free from MacKenzie Pa